Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.14952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Clin Lymphoma Myeloma Leuk
December 2024
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas.
Cancers (Basel)
September 2024
Department of Medical and Surgical Sciences, School of Medicine, University of Bologna, 40138 Bologna, Italy.
Histone deacetylase inhibitors (HDACis) are being recognized as a potentially effective treatment approach for peripheral T-cell lymphomas (PTCLs), a heterogeneous group of aggressive malignancies with an unfavorable prognosis. Recent evidence has shown that HDACis are effective in treating PTCL, especially in cases where the disease has relapsed or is resistant to conventional treatments. Several clinical trials have demonstrated that HDACis, such as romidepsin and belinostat, can elicit long-lasting positive outcomes in individuals with PTCLs, either when used alone or in conjunction with conventional chemotherapy.
View Article and Find Full Text PDFHistone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis.
Oncol Rep
October 2024
Department of Hematology, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China.
Article Synopsis
- B-cell lymphoma is hard to treat because it can behave differently and doesn't always respond well to standard treatments.
- New treatments involving immunotherapy and drugs that stop cancer from avoiding the immune system, like blocking PD-1, are being explored, but some cancers, including B-cell lymphoma, may not respond to these options.
- A study tested a combination of two treatments—a drug called romidepsin and a PD-1 blocker—on mice with B-cell lymphoma and found that together, they worked better at fighting the cancer and boosting the immune system's ability to attack the tumors.
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
Br J Haematol
November 2024
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various cancers, including B- and T-cell lymphomas. We assessed its preclinical activity as a single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphoma-derived cell lines.
View Article and Find Full Text PDFLong-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated.
J Cancer Res Ther
April 2024
Department of Hematology, Baskent University, Istanbul, Turkey.
Article Synopsis
- Angioimmunoblastic T-cell lymphoma (AITL) is a tough-to-treat subtype of peripheral T-cell lymphomas that often leads to poor patient outcomes.
- Treatment options range from traditional anthracycline-based therapies to newer drugs like romidepsin and belinostat, which have shown promise in improving survival rates.
- The case report focuses on an elderly patient with a high IPI score who, despite multiple treatment attempts, achieved lasting positive results with belinostat.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!